Philip Roland Selby1,2, Sepehr Shakib3,4, Sandra L Peake3,5, Morgyn S Warner3,6,7, David Yeung3,7,8,9, Uwe Hahn3,7,8, Jason A Roberts10,11,12. 1. School of Medicine, University of Adelaide, Adelaide, SA, Australia. Philip.Selby@sa.gov.au. 2. Pharmacy Department, Royal Adelaide Hospital, Port Road, Adelaide, SA, 5000, Australia. Philip.Selby@sa.gov.au. 3. School of Medicine, University of Adelaide, Adelaide, SA, Australia. 4. Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, SA, Australia. 5. Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Adelaide, SA, Australia. 6. Infectious Diseases Unit, The Queen Elizabeth Hospital, Adelaide, SA, Australia. 7. SA Pathology, Adelaide, SA, Australia. 8. Haematology Unit, Royal Adelaide Hospital, Adelaide, SA, Australia. 9. Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia. 10. Faculty of Medicine and Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, St Lucia, QLD, Australia. 11. Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. 12. Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Abstract
BACKGROUND: Ganciclovir (GCV) and valganciclovir (VGCV) are the first-line agents used to prevent and treat cytomegalovirus (CMV) infection in allogeneic haematopoietic stem cell transplant (alloHCT) patients. OBJECTIVE: The aim of this work was to describe available data for the clinical pharmacokinetics, pharmacodynamics and toxicodynamics of GCV and VGCV and the potential of a therapeutic drug monitoring strategy to improve outcomes in the alloHCT population. METHODS: We systematically reviewed the pharmacokinetics (dose-exposure), pharmacodynamics (exposure-efficacy) and toxicodynamics (exposure-toxicity) of GCV and VGCV in alloHCT patients with CMV infection. Studies including alloHCT patients treated for CMV infection reporting the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV or VGCV were searched for using the PUBMED and EMBASE databases from 1946 to 2019. Only studies involving participants > 12 years of age and available in the English language were included. RESULTS: A total of 179 patients were included in the 14 studies that met the inclusion criteria, of which 6 examined GCV pharmacokinetics only, while 8 also examined GCV pharmacodynamics and toxicodynamics. Reported pharmacokinetic parameters showed considerable interpatient variability and were different from other populations, such as solid organ transplant and human immunodeficiency virus-infected patients. Only one study found a correlation between neutropenia and elevated peak and trough GCV concentrations, with no other significant pharmacodynamic and toxicodynamic relationships identified. While therapeutic drug monitoring of GCV is performed in some institutions, no association between GCV therapeutic drug monitoring and clinical outcomes was identified. CONCLUSION: Further studies of the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV/VGCV in alloHCT patients are required to identify a more robust therapeutic range and to subsequently quantify the potential value of therapeutic drug monitoring of GCV/VGCV in the alloHCT population.
BACKGROUND:Ganciclovir (GCV) and valganciclovir (VGCV) are the first-line agents used to prevent and treat cytomegalovirus (CMV) infection in allogeneic haematopoietic stem cell transplant (alloHCT) patients. OBJECTIVE: The aim of this work was to describe available data for the clinical pharmacokinetics, pharmacodynamics and toxicodynamics of GCV and VGCV and the potential of a therapeutic drug monitoring strategy to improve outcomes in the alloHCT population. METHODS: We systematically reviewed the pharmacokinetics (dose-exposure), pharmacodynamics (exposure-efficacy) and toxicodynamics (exposure-toxicity) of GCV and VGCV in alloHCT patients with CMV infection. Studies including alloHCT patients treated for CMV infection reporting the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV or VGCV were searched for using the PUBMED and EMBASE databases from 1946 to 2019. Only studies involving participants > 12 years of age and available in the English language were included. RESULTS: A total of 179 patients were included in the 14 studies that met the inclusion criteria, of which 6 examined GCV pharmacokinetics only, while 8 also examined GCV pharmacodynamics and toxicodynamics. Reported pharmacokinetic parameters showed considerable interpatient variability and were different from other populations, such as solid organ transplant and human immunodeficiency virus-infectedpatients. Only one study found a correlation between neutropenia and elevated peak and trough GCV concentrations, with no other significant pharmacodynamic and toxicodynamic relationships identified. While therapeutic drug monitoring of GCV is performed in some institutions, no association between GCV therapeutic drug monitoring and clinical outcomes was identified. CONCLUSION: Further studies of the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV/VGCV in alloHCT patients are required to identify a more robust therapeutic range and to subsequently quantify the potential value of therapeutic drug monitoring of GCV/VGCV in the alloHCT population.
Authors: Vincent Emery; Mark Zuckerman; Graham Jackson; Celia Aitken; Husam Osman; Anthony Pagliuca; Mike Potter; Karl Peggs; Andrew Clark Journal: Br J Haematol Date: 2013-05-06 Impact factor: 6.998
Authors: A E Broers; R van Der Holt; J W van Esser; J W Gratama; S Henzen-Logmans; V Kuenen-Boumeester; B Löwenberg; J J Cornelissen Journal: Blood Date: 2000-04-01 Impact factor: 22.113
Authors: C M Machado; F L Dulley; L S Boas; J B Castelli; M C Macedo; R L Silva; R Pallota; R S Saboya; C S Pannuti Journal: Bone Marrow Transplant Date: 2000-08 Impact factor: 5.483
Authors: Ian Nivison-Smith; Peter Bardy; Anthony J Dodds; David D F Ma; Donna Aarons; Steven Tran; Leonie Wilcox; Jeff Szer Journal: Biol Blood Marrow Transplant Date: 2015-09-16 Impact factor: 5.742
Authors: Corinna Barkam; Haytham Kamal; Elke Dammann; Helmut Diedrich; Stefanie Buchholz; Matthias Eder; Jürgen Krauter; Arnold Ganser; Michael Stadler Journal: Bone Marrow Res Date: 2012-12-03
Authors: Maud Maillard; Li Gong; Rina Nishii; Jun J Yang; Michelle Whirl-Carrillo; Teri E Klein Journal: Pharmacogenet Genomics Date: 2022-05-30 Impact factor: 2.000